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Background
ARTEMIS was a Phase III, randomised, open-label study
assessing efficacy and safety of DRV/r 800/100mg qd
versus LPV/r 800/200mg total daily dose (qd or bid) in
treatment-naïve HIV-1-infected adults. At 96 wks, DRV/
r demonstrated non-inferiority and superiority to LPV/r
in virological response. Wk 192 results are reported.
Methods
Patients stratified by baseline (BL) viral load (VL [HIV-1
RNA] < or ≥100,000 copies/mL [cpm]) and CD4 cell
count (< or ≥200 cells/mm
3) were randomised 1:1 to
DRV/r qd or LPV/r. Primary efficacy parameter: non-
inferiority (≤ –12%) of DRV/r to LPV/r in virological
response (VL <50 cpm, ITT-TLOVR). DRV/r superiority
( ≤ 0%) was assessed if non-inferiority was demonstrated.
Results
689 patients (30% female; mean BL VL 4.85 log10 cpm;
median CD4 225 cells/mm
3) were randomised. Overall,
significantly more DRV/r than LPV/r patients had VL
<50 cpm at Wk 192, confirming DRV/r qd non-inferior-
ity (p<0.001) and superiority (p=0.002) (Table 1). In
patients with virological failure (VF; TLOVR non-VF
censored) no developing primary PI mutations were
identified in either arm; all VFs with paired BL/endpoint
phenotypes that were susceptible at BL to amprenavir,
atazanavir, indinavir, lopinavi r ,s a q u i n a v i ro rt i p r a n a v i r
remained susceptible after treatment.
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Table 1
DRV/
r
LPV/
r
DRV/r-LPV/r
[95% CI]
N% N%
VL <50cpm
(ITT-TLOVR)
All patients 343 68.8 346 57.2 11.6 [4.4-18.8]
BL VL <100,000 226 69.5 226 60.2 9.3 [0.5-18.1]
BL VL ≥100,000 117 67.5 120 51.7 15.9 [3.5-28.3]
BL CD4 <200 141 65.2 148 54.1 11.2 [-0.1-22.5]
BL CD4 ≥200 202 71.3 198 59.6 11.7 [2.4-21.0]
VL <50cpm
(sensitivity analyses)
TLOVR non-VF
censored
270 87.4 245 80.8 6.6 [0.3-12.9]
On protocol TLOVR 340 69.1 345 57.1 12.0 [4.8-19.2]
Missing=failure 343 68.5 346 60.1 8.4 [1.3-15.5]
FDA snapshot 343 68.5 346 59.8 8.7 [1.5-15.8]
Treatment-emergent
adverse events (AEs)
AEs leading to
permanent stop of
study medication
343 7.6 346 14.5 p=0.005*
Grade 2-4 treatment-
related diarrhoea
343 5.0 346 11.3 p=0.003*
Changes in lipid
parameters, median
increase mmol/L (min;
max)
Triglycerides
‡ 254 0.1
(-5; 3)
228 0.6 (-3;
10)
p<0.0001
¶
Total cholesterol
§ 254 0.6
(-2; 4)
228 1.0 (-1;
4)
p<0.0001
¶
*Fisher’s Exact test;
‡NCEP normal level <1.69mmol/L;
§NCEP normal level
<5.17mmol/L;
¶Wilcoxon Rank Sum test
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DRV/r qd demonstrated sustained efficacy with non-
inferiority and superiority to LPV/r over 192 wks. Devel-
opment of resistance was low in both arms. DRV/r was
associated with smaller median increases in total choles-
terol and triglycerides than LPV/r, and a lower incidence
of grade 2–4 diarrhoea.
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